Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 among infants with sickle cell disease

Pediatrics

Volumn 106, Issue 5 I, 2000, Pages 965-972

  O'Brien, Katherine L ^a,b   Swift, Andrea J ^b   Winkelstein, Jerry A ^b   Santosham, Mathuram ^a,b   Stover, Beth ^b   Luddy, Ruth ^c   Gootenberg, Joseph E ^d   Nold, Jeffrey T ^e   Eskenazi, Allen ^f   Snader, Sally J ^b   Lederman, Howard M ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SINAI HOSPITAL OF BALTIMORE   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Annapolis Dermatology Center   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Conjugate vaccine; Pneumococcus; Prevnar; Sickle cell disease

Indexed keywords

PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; MALE; PRIORITY JOURNAL; SEROTYPE; SICKLE CELL ANEMIA;

EID: 0033744553     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.106.5.965     Document Type: Article

References (27)

1. Prophylaxis with oral penicillin in children with sickle cell anemia
2. Polysaccharide encapsulated bacterial infection in sickle cell anemia: A thirty year epidemiologic experience
3. Infection caused by Streptococcus pneumoniae in children with sickle cell disease: Epidemiology, immunologic mechanisms, prophylaxis and vaccination
4. Mortality in children and adolescents with sickle cell disease
5. Prevention Mortality among children with sickle cell disease identified by newborn screening during 1990-1994 - California, Illinois, and New York
6. National trends in mortality of children with sickle cell disease, 1968 through 1992
7. Experience with the use of prophylactic penicillin in children with sickle cell anemia
8. Functional asplenia in sicklecell anemia
9. Deficiency of pneumococcal serum opsonizing activity in sickle-cell disease
10. An abnormality of the alternate pathway of complement activation in sickle-cell disease
11. Pneumococcal infections in sickle cell disease
12. Increased susceptibility of splenectomized rats to infection with Diplococcus pneumoniae
13. Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy
14. Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease
15. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants
16. Serum antibodies to pneumococcal C polysaccharide in children: Response to acute pneumococcal otitis media or to vaccination
17. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S
18. Serum opsonic activity in infants with sickle cell disease immunized with pneumococcal polysaccharide protein-conjugate vaccine
19. Serologic follow-up of children with sickle cell disease immunized with a Haemophilus influenzae type b conjugate vaccine during early infancy
20. Immunization of young infants with sickle cell disease with a Haemophilus influenzae type b saccharide-diphtheria CRM197 protein conjugate vaccine
21. Haemophilus influenzae type b immunization of children with sickle cell disease
22. Direct evidence that decreased serum opsonization of Streptococcus pneumoniae via the alternative pathway in sickle cell disease is related to antibody deficiency
23. Lack of a requirement for the FC region of IgG in restoring pneumococcal opsonization via the alternative complement pathway in sickle cell disease
24. Complement and immunoglobulin levels in early childhood in homozygous sickle cell disease